{"id":18252,"date":"2014-07-17T04:30:00","date_gmt":"2014-07-17T02:30:00","guid":{"rendered":"http:\/\/www.fedaiisf.it\/big-pharma-novartis-ringrazia-cina-russia\/"},"modified":"2014-07-17T04:30:00","modified_gmt":"2014-07-17T02:30:00","slug":"big-pharma-novartis-ringrazia-cina-russia","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/big-pharma-novartis-ringrazia-cina-russia\/","title":{"rendered":"Big Pharma, Novartis thanks China, Russia\u2026"},"content":{"rendered":"

 Under <\/span><\/span>investigation by the prosecutor of Siena for<\/span><\/strong><\/a> <\/span>fraud<\/b> regarding the 2009 supply of the swine flu vaccine, and in the antitrust's crosshairs with <\/span><\/span>L<\/span>accused of having cartel<\/span><\/strong><\/a> with <\/span>Roche <\/b>regarding the price of a drug (Avastin-Leucentis), <\/span>Novartis<\/b> he consoles himself with the sales figures that come from further afield. In fact, the Swiss pharmaceutical giant declared that it benefited from a 2% leap in revenues in the second quarter of 2014, which occurred mainly thanks to emerging markets: sales in <\/span>China<\/b>, <\/span>Russia<\/b> and other emerging markets would in fact have increased by 8%, while the revenues generated by the growth of products launched since 2009 or which have market exclusivity until 2018, increased by 18%. A result that comes just as \u2013 as reported by \u00abThe Wall Street Journal\u00bb \u2013 the company is preparing for a review of its organization and its areas of interest.
<\/span> <\/span><\/p>\n

The Basel-based company, permanent member of Big Pharma<\/b>, would be about to complete a series of operations announced earlier this year and focused on the area of generic drugs<\/b> and eye care, and is selling its holdings in diagnostics and vision companies to competitors GlaxoSmithKline and Eli Lilly and Co. animal care<\/b>. A series of deals valued at more than $25 billion that are expected to be completed in the first half of 2015.<\/span><\/span><\/p>\n

<\/span><\/p>\n

July 17, 2014 \u2013 <\/span><\/b>values Sotto indagine della procura di Siena per truffa riguardo la fornitura nel 2009 del vaccino contro l’influenza suina, e nel mirino dell’antitrust con l’accusa di aver fatto cartello insieme a Roche riguardo il prezzo di un farmaco (Avastin-Leucentis), Novartis si consola coi dati di vendita che arrivano da più lontano. Il gigante farmaceutico svizzero ha infatti dichiarato di aver beneficiato …<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-18252","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/18252","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=18252"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/18252\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=18252"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=18252"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=18252"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}